Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan-Reference-Cited by-同舟云学术

Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan

Published:2018-11-26 Issue:1 Volume:33 Page:45-52
ISSN:1178-2595
Container-title:Pharmaceutical Medicine
language:en
Short-container-title:Pharm Med

Author:

Nakayama Hiroki^ORCID,Matsumaru Naoki,Tsukamoto Katsura

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40290-018-0260-8/fulltext.html

Reference22 articles.

1. Mol PG, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG, Haaijer-Ruskamp FM, et al. Post-approval safety issues with innovative drugs: a European cohort study. Drug Saf. 2013;36(11):1105–15.

2. Fujikawa M, Ono S. Analysis of safety-related regulatory actions for new drugs in Japan by nature of identified risks. Pharm Med. 2017;31(5):317–27.

3. Coulson A, Levy A, Gossell-Williams M. Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J. 2014;63(6):650–4.

4. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228(1):18–28.

5. Nakayama H, Tsukamoto K. Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan. Investig New Drugs. 2018;36(4):702–8.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the Challenges Associated with Approval of Anticancer Products to Facilitate the Regulatory Approvals: A Cross-sectional Study;Current Cancer Therapy Reviews;2024-11

2. Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risks;Expert Opinion on Drug Safety;2021-07-15